Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy

被引:18
作者
Fang, Chao [1 ,2 ]
Li, Xiang-Ping [3 ]
Gong, Wei-Jing [1 ,2 ]
Wu, Na-Yiyuan [1 ,2 ]
Tang, Jie [1 ,2 ]
Yin, Ji-Ye [1 ,2 ]
Li, Xi [1 ,2 ]
Zhang, Wei [1 ,2 ]
Zhou, Hong-Hao [1 ,2 ,4 ]
Liu, Zhao-Qian [1 ,2 ,4 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China
[2] Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China
[3] Cent S Univ, Dept Pharm, Xiangya Hosp, Changsha, Hunan, Peoples R China
[4] Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China
基金
中国国家自然科学基金;
关键词
lung cancer; miRNA; platinum-based chemotherapy; polymorphism; toxicity; FUNCTIONAL POLYMORPHISM; HIGH-RISK; MICRORNAS; SUSCEPTIBILITY; BIOMARKERS; MIR-146A; EXPRESSION; SURVIVAL; MIR-27; GENES;
D O I
10.1111/1440-1681.12704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platinum-based chemotherapy toxicity severely impedes successful treatment in lung cancer patients. MicroRNAs (miRs) have a significant impact on the occurrence and survival rate of lung cancer. The purpose of this study was to investigate the association between common miRNA variants and platinum-based chemotherapy toxicity in lung cancer patients. A total of eight functional single nucleotide polymorphisms (SNPs) of miRNA were genotyped in 408 lung cancer patients by MALDI-TOF mass spectrometry. All the patients were histologically confirmed as lung cancer, and were treated with platinum-based chemotherapy for at least two cycles. It was found that the polymorphism rs2042553 of miR-5197 had a significant association with overall severe toxicity in both additive (P=.031, odds ratio [OR]=1.41, 95% confidence interval [CI] 1.03-1.93) and dominant (P=.009, OR=1.80, 95% CI 1.16-2.80) models. MiR-605 rs2043556 was significantly related to severe hepatotoxicity in dominant model (P=.022, OR=2.51, 95% CI 1.12-4.14). In addition, rs2910164 of miR-146a had marginal statistical effect on severe hepatotoxicity in additive model (P=.054). The subgroup analyses showed that miR-27a rs895819 was related to gastrointestinal toxicity in age >56years old, smoking and non-smoking patients. Taken together, our results revealed that polymorphisms of miR-5197, miR-605, miR-146a, and miR-27a contributed to the chemotherapy toxicity of lung cancer, which may serve as a predictive tool for toxicity evaluation of platinum-based chemotherapy in lung cancer patients.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [41] Association of NQO1Pro187Ser polymorphism with clinical outcomes and survival of lung cancer patients treated with platinum chemotherapy
    Walia, Harleen Kaur
    Singh, Navneet
    Sharma, Siddharth
    PERSONALIZED MEDICINE, 2021, 18 (04) : 333 - 346
  • [42] RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer
    Chu, Tian-qing
    Li, Rong
    Shao, Min-hua
    Ye, Jun-yi
    Han, Bao-hui
    ACTA PHARMACOLOGICA SINICA, 2016, 37 (11) : 1490 - 1498
  • [43] HADHA is a Potential Predictor of Response to Platinum-based Chemotherapy for Lung Cancer
    Kageyama, Taihei
    Nagashio, Ryo
    Ryuge, Shinichiro
    Matsumoto, Toshihide
    Iyoda, Akira
    Satoh, Yukitoshi
    Masuda, Noriyuki
    Jiang, Shi-Xu
    Saegusa, Makoto
    Sato, Yuichi
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (12) : 3457 - 3463
  • [44] Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients
    Han, Baohui
    Gao, Ge
    Wu, Wenting
    Gao, Zhiqiang
    Zhao, Xueying
    Li, Ling
    Qiao, Rong
    Chen, Hongyan
    Wei, Qingyi
    Wu, Jinchang
    Lu, Daru
    LUNG CANCER, 2011, 72 (02) : 238 - 243
  • [45] Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Aimi
    Ma, Meili
    Jin, Bo
    Han, Baohui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 5241 - 5248
  • [46] Genetic polymorphisms in the mEH gene in relation to tobacco smoking: role in lung cancer susceptibility and survival in north Indian patients with lung cancer undergoing platinum-based chemotherapy
    Walia, Harleen Kaur
    Singh, Navneet
    Sharma, Siddharth
    FUTURE ONCOLOGY, 2021, 17 (35) : 4925 - 4946
  • [47] XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients
    Peng, J.
    Chen, Y. Y.
    Yang, L. X.
    Zhao, X. Y.
    Gao, Z. Q.
    Yang, J.
    Wu, W. T.
    Wang, H. J.
    Wang, J. C.
    Qian, J.
    Chen, H. Y.
    Jin, L.
    Bai, C. X.
    Han, B. H.
    Lu, D. R.
    LUNG CANCER, 2013, 80 (03) : 333 - 338
  • [48] Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
    Liu, Di
    Xu, Wen
    Ding, Xi
    Yang, Yang
    Su, Bo
    Fei, Ke
    JOURNAL OF CANCER, 2017, 8 (18): : 3785 - 3794
  • [49] Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy
    Butkiewicz, Dorota
    Drosik, Anna
    Suwinski, Rafal
    Krzesniak, Malgorzata
    Rusin, Marek
    Kosarewicz, Agata
    Rachtan, Jadwiga
    Matuszczyk, Iwona
    Gawkowska-Suwinska, Marzena
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (07) : E1100 - E1108
  • [50] Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
    Tao, Kai-Yi
    Li, Xian-Xing
    Xu, Wei-Zhen
    Wang, Yin
    Zhu, Shuang-Mei
    Xie, Hua-Xia
    Luo, Wen-Hua
    Xu, Yan-Jun
    Xu, Xiao-Ling
    ONCOTARGETS AND THERAPY, 2015, 8 : 147 - 155